BIBLIOGRAFIA:
1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and
chloroquine effectively inhibit the recently emerged novel coronavirus
(2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
2. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al.
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is
Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.
mBio. 06 de 2018;9(2).
3. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC,
et al. Remdesivir for the Treatment of Covid-19 - Preliminary Report. N
Engl J Med. 22 de mayo de 2020;
4. Ritonavir Dosificación, Efectos secundarios [Internet]. infoSIDA.
[citado 11 de junio de 2020]. Disponible en:
https://infosida.nih.gov/drugs/244/ritonavir/0/patient
5. Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al. Role
of lopinavir/ritonavir in the treatment of SARS: initial virological and
clinical findings. Thorax. 1 de marzo de 2004;59(3):252-6.
6. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease
2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.
7. Lineamientos tecnicos para la atención clinica de personas con
COVID-19. Ministerio de Salud (MINSAL) [Internet]. Disponible en:
http://asp.salud.gob.sv/regulacion/pdf/lineamientos/lineamientostecnicosparalaatencionclinicadepersonasconCOVID19TE.pdf
8. Lopinavir/Ritonavir and Other HIV Protease Inhibitors |
Coronavirus Disease COVID-19 [Internet]. COVID-19 Treatment
Guidelines. [citado 12 de junio de 2020]. Disponible en:
https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/lopinavir-ritonavir-and-other-hiv-protease-inhibitors/
9. Hoja informativa para proveedores de atención médica autorización de
uso urgente (EUA) de fosfato de cloroquina proporcionado por la reserva
estratégica nacional para el tratamiento del covid-19 en ciertos
pacientes hospitalizados [Internet]. [Citado 12 de junio de
2020]. Disponible en: https://www.fda.gov/media/137437/download
10. Wong CK, Lam CWK, Wu AKL, Ip WK, Lee NLS, Chan IHS, et al. Plasma
inflammatory cytokines and chemokines in severe acute respiratory
syndrome. Clin Exp Immunol. abril de 2004;136(1):95-103.
11. Qin Y-Y, Zhou Y-H, Lu Y-Q, Sun F, Yang S, Harypursat V, et al.
Effectiveness of glucocorticoid therapy in patients with severe
coronavirus disease 2019: protocol of a randomized controlled trial.
Chinese Medical Journal. 5 de mayo de 2020;133(9):1080–1086.
12. Bosseboeuf E, Aubry M, Nhan T, de Pina JJ, Rolain JM, Raoult D,
et al. Azithromycin Inhibits the Replication of Zika Virus. J Antivir
Antiretrovir [Internet]. 2018 [citado 14 de junio de
2020];10(1). Disponible en:
https://www.omicsonline.org/open-access/azithromycin-inhibits-the-replication-of-zika-virus-1948-5964-1000173-99806.html
13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and
risk factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: a retrospective cohort study. The Lancet. marzo de
2020;395(10229):1054-62.
14. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero
J, et al. Association of Treatment With Hydroxychloroquine or
Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New
York State. JAMA. 11 de mayo de 2020;
15. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL,
et al. Deployment of convalescent plasma for the prevention and
treatment of COVID-19. J Clin Invest. 01 de 2020;130(6):2757-65.
16.lineamientostecnicosparausodeplasmaconvalecienteenpacientesconCOVID19-Acuerdo821_v2.pdf
[Internet]. [citado 14 de junio de 2020]. Disponible
en:http://asp.salud.gob.sv/regulacion/pdf/lineamientos/lineamientostecnicosparausodeplasmaconvalecienteenpacientesconCOVID19-Acuerdo821_v2.pdf
17. Dumont LJ, Cancelas JA, Maes LA, Rugg N, Whitley P, Herschel L,
et al. The bioequivalence of frozen plasma prepared from whole blood
held overnight at room temperature compared to fresh-frozen plasma
prepared within eight hours of collection. Transfusion. marzo de
2015;55(3):476-84.
18. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL,
et al. Evidence that Vitamin D Supplementation Could Reduce Risk of
Influenza and COVID-19 Infections and Deaths. Nutrients. 2 de abril de
2020;12(4).